{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477165149
| image = Buserelin.svg
<!--Clinical data-->
| tradename = Etilamide
| Drugs.com = {{drugs.com|CONS|buserelin}}
| pregnancy_category = X
| legal_status = ℞-only
| routes_of_administration = [[Implant (medicine)|implant]], intranasal
<!--Pharmacokinetic data-->
| elimination_half-life = 72 to 80 minutes
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| IUPHAR_ligand = 3860
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57982-77-1
| ATC_prefix = L02
| ATC_suffix = AE01
| ATC_supplemental = {{ATCvet|H01|CA90}}
| PubChem = 50225
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06719
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1909304
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 45545
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PXW8U3YXDV
| synonyms = D-Ser(Tbu)<sup>6</sup>EA<sup>10</sup>LHRH
<!--Chemical data-->
| C=60 | H=86 | N=16 | O=13
| molecular_weight = 1239.42 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)/t40-,41-,42-,43-,44-,45-,46-,47+,48-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CUWODFFVMXJOKD-UVLQAERKSA-N
| smiles = CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@@H]6CCC(=O)N6
}}

'''Buserelin''' ([[International Nonproprietary Name|INN]]) is a [[gonadotropin-releasing hormone agonist]] ([[GnRH]] agonist).  The drug's effects are dependent on the frequency and time course of administration.  GnRH is released in a pulsatile fashion in the postpubertal adult.  Initial interaction of any GnRH agonist, such as buserelin, with the GnRH receptor induces release of [[follicle-stimulating hormone]] (FSH) and [[luteinizing hormone]] (LH) by gonadotrophes.  Long-term exposure to constant levels of buserelin, rather than endogenous pulses, leads to downregulation of the GnRH receptors and subsequent suppression of the pituitary release of LH and FSH.<ref name="Austria-Codex">{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=62nd|isbn=978-3-85200-181-4|pages=7832–7|language=German}}</ref><ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=372–3|isbn=3-8047-1763-2}}</ref><ref>{{cite journal|pmid=8917899|year=1996|author1=Wuttke|first1=W|title=The neurochemistry of the GnRH pulse generator|journal=Acta neurobiologiae experimentalis|volume=56|issue=3|pages=707–13|last2=Jarry|first2=H|last3=Feleder|first3=C|last4=Moguilevsky|first4=J|last5=Leonhardt|first5=S|last6=Seong|first6=J. Y.|last7=Kim|first7=K|url=http://www.ane.pl/linkout.php?vol=56&no=3&fpp=707}}</ref>

Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as [[prostate cancer]] or [[breast cancer]], estrogen-dependent conditions (such as [[endometriosis]] or [[uterine fibroids]]), and in [[Reproductive technology|assisted reproduction]].<ref name="Mutschler" />

It is normally delivered via a [[nasal spray]], but is also available as an injection.<ref name="Austria-Codex" />

Buserelin acetate is marketed by [[Sanofi-Aventis]] under the brand name '''Suprefact'''<ref name="Austria-Codex" /> and a generic form of buserelin is now produced by [[CinnaGen]] under the brand name '''CinnaFact'''.

Buserelin is also marketed under the brand name '''Metrelef'''. Metrelef is approved to treat patients with [[endometriosis]] by suppression of ovarian hormone production. In [[ovulation induction]] It is used as a [[pituitary]] blockade as an adjunct to [[gonadotrophin]] administration.

[[Deslorelin]] is a similar GnRH agonist used in veterinary medicine.

==Adverse effects==
During the initial phase of the therapy, before GnRH receptors have been significantly down-regulated, [[testosterone]] levels are increased. This can lead to transient tumour activation with bone pain (in patients with metastases) and [[urinary retention]]. Side effects that occur later during the treatment are mainly due to low testosterone levels and include headache, [[hot flashes]], reduced [[libido]], and [[erectile dysfunction]].<ref name="Austria-Codex" />

==See also==
* [[Leuprorelin]]

==References==
{{Reflist|35em}}

{{Gonadotropins and GnRH}}
{{Peptidergics}}

[[Category:GnRH agonists]]
[[Category:World Anti-Doping Agency prohibited substances]]